Baillie Gifford & Co
BPMC

Baillie Gifford & Co’s Blueprint Medicines BPMC Stock Holding History

Baillie Gifford & Co’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-315
Closed -$14.2K – 320
2023
Q1 		$14.2K Hold
315
– – ﹤0.01% 371
2022
Q4 		$13.8K Hold
315
– – ﹤0.01% 384
2022
Q3 		$21K Hold
315
– – ﹤0.01% 325
2022
Q2 		$16K Hold
315
– – ﹤0.01% 361
2022
Q1 		$20K Hold
315
– – ﹤0.01% 361
2021
Q4 		$34K Sell
315
-28
-8% -$2.93K ﹤0.01% 312
2021
Q3 		$35K Sell
343
-61
-15% -$5.68K ﹤0.01% 305
2021
Q2 		$36K Sell
404
-22
-5% -$2.02K ﹤0.01% 303
2021
Q1 		$41K Buy
+426
New +$42.5K ﹤0.01% 289

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Baillie Gifford & Co's BPMC Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Blueprint Medicines (BPMC) in Q2 2023, closing a stake of 315 shares — an estimated $14.2K sold.

Baillie Gifford & Co first reported a position in BPMC in Q1 2021 and held it in 9 quarters. The position peaked at $41K in Q1 2021. 222 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Blueprint Medicines position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 315 Blueprint Medicines shares in Q2 2023, an estimated $14.2K.
  • Baillie Gifford & Co first reported a position in Blueprint Medicines in Q1 2021 and held it in 9 quarters.
  • Baillie Gifford & Co's Blueprint Medicines position peaked at $41K in Q1 2021.
  • 222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.